TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02901301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg, IV, q3weeks, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6mg/kg (8mg loading dose), IV, q3weeks, Day 1
Study: NCT04005456

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.
Study: NCT02901301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, PO, BID, Day 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2 (level 1), IV, q3weeks, Day 1
Study: NCT04005456

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral change support program
Description: Program to implement lifestyle and behavioral change according to individuals' need.
Study: NCT01134861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area \< 1.7 m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: 5 mg/m2 i.v. bolus weekly first 5 weeks of RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 5 mg/m2 i.v. bolus weekly first 5 weeks of RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
Study: NCT04438798

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: F Group
Description: In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: H Group
Description: In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
Study: NCT02275013

Intervention type: DRUG
Intervention: Levosimendan

Intervention type: DRUG
Intervention: Levosimendan
Study: NCT01816685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Study: NCT02783053

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Metformin vs no metformin
Study: NCT03055923

Intervention type: DEVICE
Intervention: The Inflammacheck Device
Description: A new hand-held, Non-invasive breathing test, that only requires tidal breathing.

Intervention type: DEVICE
Intervention: The Inflammacheck Device
Description: A new hand-held, Non-invasive breathing test, that only requires tidal breathing.

Intervention type: DEVICE
Intervention: The Inflammacheck Device
Description: A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
Study: NCT02485314

Intervention type: OTHER
Intervention: Participation
Description: The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
Study: NCT04055259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Health and Wellness Coaching
Description: Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
Study: NCT04322760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch with Dexmedetomidine Bupivacaine
Description: 10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Bupivacaine
Description: 10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
Study: NCT00585871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 0.1 mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: 25 mg tid
Study: NCT05052502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case Management and Follow-up
Description: Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management and Follow-up
Description: Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reactive focal mass drug administration (rfMDA)
Description: Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials.~For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants.
Study: NCT04668521

Intervention type: OTHER
Intervention: OVA360
Description: Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection

Intervention type: OTHER
Intervention: OVA360
Description: Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection

Intervention type: OTHER
Intervention: OVA360
Description: Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
Study: NCT05114369

Intervention type: PROCEDURE
Intervention: Curative surgery
Study: NCT02529371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UriCap-RM
Description: UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
Study: NCT01805206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of urinary iFABP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of enteral feedings
Study: NCT01317823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of cervical status
Description: Assessment of cervical status based on Bishop score versus sonographically measured cervical length

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of cervical status
Description: Assessment of cervical status based on Bishop score versus sonographically measured cervical length
Study: NCT03815383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
Study: NCT03282981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Topical application of Timolol on non-healing diabetic foot ulcers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non biologically active gel
Description: Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
Study: NCT00370370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Injection of intravitreal bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab + triamcinolone acetonide
Description: Injection of bevacizumab + triamcinolone acetonide
Study: NCT02925936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid facing the anode end of xray machine
Description: Thyroid position: facing the anode end of xray machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid facing the cathode end of xray machine
Description: Thyroid position: facing the cathode end of xray machine
Study: NCT04289259

Intervention type: OTHER
Intervention: TMB assessment
Description: Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).

Intervention type: OTHER
Intervention: TMB assessment
Description: Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).

Intervention type: OTHER
Intervention: TMB assessment
Description: Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
Study: NCT02549417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study: NCT04325009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab
Description: 1. st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab
Description: 1. st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Lipitor 80mg Tab
Study: NCT01138371

Intervention type: PROCEDURE
Intervention: LDL Apheresis
Description: LDL Apheresis
Study: NCT01811498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT01011699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotinamide
Description: Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevelamer
Description: Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: After 6 months of treatment, patient screening on PTH level:~For patients with PTH \> 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: After 6 months of treatment, patient screening on PTH level:~For patients with PTH \> 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l.
Study: NCT04311190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family engagement
Description: Physical exercises and simple care tasks
Study: NCT01727206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Study: NCT02806505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
Study: NCT04387045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guilty feelings
Description: Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Guilty feelings
Description: Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
Study: NCT02377323

Intervention type: OTHER
Group type: OTHER
Intervention: MACFIMS
Description: Cognitive evaluation of 50 participants

Intervention type: OTHER
Group type: OTHER
Intervention: MACFIMS
Description: Cognitive evaluation of 50 participants

Intervention type: OTHER
Group type: OTHER
Intervention: MSQoL-54
Description: Quality of life questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: MSQoL-54
Description: Quality of life questionnaires
Study: NCT01826045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-gamma Glutamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03142256

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentivised - Conditional Cash Transfer
Description: Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada 200Mg-300Mg Tablet
Description: Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
Study: NCT02372942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lattoferrin
Description: 515 pregnant women using lattoferrin to prevent preterm delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
Study: NCT03843645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: surgical procedure under general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia
Description: surgical procedure under regional anesthesia
Study: NCT00549471

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: physiotherapy
Description: CG children will undergo a program of intensive physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A and physiotherapy
Description: BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
Study: NCT05849792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and psychological intervention
Description: Physical Exercise Intervention~Sixty-minute sessions were delivered via internet, three times per week (1 supervised) over the first four weeks of the COVID-19 home confinement. The intervention was a multicomponent exercise program lead by a specialist in fitness composed of aerobic, resistance, balance, coordination, mobility and stretching exercises. Each multicomponent exercise session consisted of a 10 min warm-up, 40 min of moderate to vigorous intensity physical activity, and 10 min cool down.~Psychological intervention~The internet-based-psychological intervention provided to different component of Cognitive Behavioral Therapy (CBT) guided and recorded by a sport neuro-psychologist specialist. The iCBT is based on the protocol for face-to-face CBT for depression. The program consisted of 4 weeks composed of 2 weekly video-guided sessions, with a maximum duration of 30 minutes. iCBT was focused on 4 main axes of action physiological, emotional, behavioral and cognitive.
Study: NCT02679456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole